on the morning of june 23, the bidding for the fifth batch of national centralized procurement of pharmaceutical drugs organized by the national healthcare security administration and other relevant departments was opened in shanghai. more than 200 pharmaceutical enterprises, including hybio pharmaceutical, attended the bidding. the company’s essential product of thymalfasin for injection was successfully selected at a good price, shortly before it just passed the consistency evaluation.
after trimetazidine dihydrochloride modified release tablets won the bidding in the second batch of national centralized procurement, hybio pharmaceutical’s another blockbuster product successfully won the bidding. according to market statistics, the sales of this product was nearly rmb 1.1 billion in 2020. winning the bid is conducive to the company to expand its market share and improve its core competitiveness.
thymalfasin is a chemically synthesized peptide immunomodulator composed of 28 amino acids. clinically, it is mainly used for adjuvant therapy of patients with chronic hepatitis b, chronic virus infection, tumor and immunodeficiency. it can enhance the immune response of the body to antivirus, anti-bacteria and anti-tumor.
during covid-19 in 2020, hybio pharmaceutical’s thymalfasin for injection was widely used in the first line of anti-epidemic to improve the antiviral immunity ability of front-line medical staff and was listed as the prevention and control drug by many local medical departments. according to the provisions of the national centralized drug procurement documents issued by the joint procurement office, if the actual number of selected enterprises in the country is 4 or more, the agreed purchase amount in the first year shall be 80% of the calculation base of the agreed purchase amount in the first year. the procurement cycle shall be 3 years in principle.
62 kinds of drugs were included in the centralized procurement of drugs organized by the country. in 2020, the procurement amount on provincial platforms reached rmb 55 billion, setting a new record for centralized procurement. in terms of the dosage form of the purchased drugs, injections accounted for half, and the amount of money involved accounted for 70% and became the main dosage form of the centralized purchase.